Upstream Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UPB research report →
Range $25 – $25
Price Chart
About the company
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor.
- CEO
- E. Rand Sutherland
- IPO
- 2024
- Employees
- 75
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on UPB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $87.15M
- P/E
- -0.68
- PEG
- 0.03
- P/S
- 39.15
- P/B
- 0.48
- EV/EBITDA
- -0.40
- Div Yield
- 0.00%
- Gross Margin
- 98.29%
- Op Margin
- -6115.99%
- Net Margin
- -5712.33%
- ROE
- -57.09%
- ROIC
- -74.77%
Latest fiscal year · YoY change
- Revenue
- $2.85M+20.4%
- Gross Profit
- $2.85M+20.4%
- Op Income
- $-160,361,000
- Net Income
- $-143,443,000-128.4%
- EPS
- $-2.66-78.5%
- OCF Growth
- -125.2%
- FCF Growth
- -123.6%
- 52W High
- $33.68
- 52W Low
- $1.56
- 50D MA
- $3.93
- 200D MA
- $7.32
- Beta
- 1.39
- RSI (14)
- 23
- Avg Volume
- 993.16K
No earnings-call transcripts are available for UPB yet.
- Free Float
- 36.9%
- Shares Outstanding
- 54.81M
- Float Shares
- 20.23M
of shares held by institutions
153 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 8.18M | ▲ 18.69K |
| Orbimed Advisors LLC | 5.69M | 0 |
| Norges Bank | 3.77M | ▲ 3.77M |
| Blackrock, Inc. | 3.69M | ▼ 66.05K |
| Decheng Capital LLC | 2.72M | 0 |
| Enavate Sciences Gp, LLC | 2.46M | 0 |
| Vanguard Group Inc | 2.39M | ▼ 54.11K |
| Vanguard Capital Management LLC | 1.96M | ▲ 82.60K |
| Jpmorgan Chase & Co | 1.46M | ▲ 446.64K |
| D. E. Shaw & Co., Inc. | 1.40M | ▲ 362.69K |
| Millennium Management LLC | 1.17M | ▲ 24.41K |
| Goldman Sachs Group Inc | 1.13M | ▲ 879.98K |
Held by 172 ETFs
Biggest fund positions in UPB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | GRAY MICHAEL | sell | 853 |
| Sep 16, 26 | Ambrose Allison | sell | 485 |
| Sep 16, 26 | Deykin Aaron | sell | 895 |
| Sep 16, 26 | Sutherland Everett Rand | sell | 2,095 |
| Sep 16, 26 | Houghton Adam | sell | 700 |
| Jun 16, 26 | GRAY MICHAEL | sell | 853 |
| Jun 16, 26 | Sutherland Everett Rand | sell | 2,095 |
| Jun 16, 26 | Houghton Adam | sell | 700 |
| Jun 16, 26 | Deykin Aaron | sell | 895 |
| Jun 16, 26 | Ambrose Allison | sell | 477 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our UPB coverage
Recent articles, reports, and earnings notes.
Want a deeper read on UPB?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Upstream Bio, Inc. (NASDAQ:UPB) Stock Has Average Price Target of $29.67 According to Analysts
defenseworld.net · Nov 11
Upstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 10
Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress
globenewswire.com · Nov 10
Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
defenseworld.net · Oct 5
These beaten-down stocks could bounce back in January, if history is any guide
marketwatch.com · Sep 21
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
globenewswire.com · Sep 8
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
globenewswire.com · Sep 1
Fannie Mae Announces Sale of Non-Performing Loans
gurufocus.com · Aug 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
